An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
about
Ezetimibe therapy: mechanism of action and clinical updateOrigin and therapy for hypertriglyceridaemia in type 2 diabetesTesting cardiovascular drug safety and efficacy in randomized trialsLimitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.Niacin or ezetimibe for patients with, or at risk of coronary heart diseaseCombination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemiaEzetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potencyConsidering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefitsEconomic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia.Evolving targets for lipid-modifying therapyResponse by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With HypercholesterolemiaWhat combination therapy with a statin, if any, would you recommend?Therapies targeting exogenous cholesterol uptake: new insights and controversies.Pharmacological strategies for lowering LDL cholesterol: statins and beyond.Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.A case study of single-pill combination therapy: the ezetimibe/simvastatin combination for treatment of hyperlipidemia.Beyond statins: lipid management to reduce cardiovascular risk.Demystifying the management of hypertriglyceridaemia.Critical review of non-statin treatments for dyslipoproteinemia.Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.Improving the odds: ezetimibe and cardiovascular disease.Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.All at sea: new lipid-lowering drug trials continue to disappoint.
P2860
Q24630302-14A99D4A-9842-475E-AF3C-F8989B3FBB2BQ26824004-C6F32D10-D267-44A3-A666-0BD4EA64BD73Q26849771-C958E461-255D-4A80-BBF5-F40EA47B1F98Q33559274-2C5267A3-B301-46CC-9B26-7E7DE2705243Q33824019-917EBC40-53EC-4AAD-BC40-459A73DDA7B0Q34300722-EDF4BBEA-B3F5-4C9B-91B5-5551F78C2A34Q34334828-79756BFC-3228-49FE-A4B9-6E0F347D640EQ34353742-0BC97A4B-0BE3-4ED3-883B-A7ABC6F29308Q34566253-195B9D0B-05FB-4792-8733-F6371C912D20Q34801961-DB440BD7-3762-4AFE-ABC9-AE5C4719F4CAQ34880292-F8B1DA68-AA5E-47FD-B2DE-78CC63B0BAF9Q35233116-767BF6BE-D088-4734-9DDF-251790039377Q37324420-EB00DCA9-EFC4-4BC8-AF40-31E98C4C50EAQ37636914-5A8FB421-6004-4980-959B-6EEBE3AED29AQ37812296-BED5D7F9-8815-4D96-8A76-C3685A851965Q37824292-138C3804-8307-4B6A-9FD7-8F44E3679BABQ37842120-DFB36C58-B525-4115-B6D5-167FEC283FDDQ38011919-816C8323-96B8-44A6-84DA-15844A2A2B62Q38020453-E4D60D08-72CC-41DA-941A-F4DD211F5050Q38036194-BA61EDB3-E65E-4D67-BED7-91018E63467DQ38100747-EA18E89C-B503-4FD2-95E4-C70429F84B6CQ38141575-B0AF39D1-BCA0-42C5-B9EF-00287EA75492Q38186099-EF791EF6-1FE8-4539-A2D5-1D5C0078F695Q38207925-BA2AFBFB-CA2D-4BC9-B7A7-81E2975468CFQ38217797-1618E95A-CD85-4C4B-B4DC-20FFDBA7C9CBQ38393758-4B367CBA-1F49-4607-AB83-B54A592F86D1Q38777322-0EA41D61-D6BB-4B38-87E9-EBDA5F2EE7D1Q42936079-66FE041F-94C4-49FE-8A6D-4E7BE18F1E96Q43430988-D0BB8464-AFC3-41BD-8EB4-67B4E76AAC0CQ44157908-BDF329F4-2600-4D78-8C77-2D3531AEC948Q45420980-B7B85131-7F97-4F67-8F3A-7D1C36CE6420
P2860
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
An update on the IMProved redu ...... nal Trial (IMPROVE-IT) design.
@en
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial
@nl
type
label
An update on the IMProved redu ...... nal Trial (IMPROVE-IT) design.
@en
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial
@nl
prefLabel
An update on the IMProved redu ...... nal Trial (IMPROVE-IT) design.
@en
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial
@nl
P2093
P50
P1476
An update on the IMProved redu ...... nal Trial (IMPROVE-IT) design.
@en
P2093
Carolyn H McCabe
Christopher P Cannon
Michael A Blazing
Michael E Stepanavage
Richard C Pasternak
Thomas A Musliner
P304
P356
10.1016/J.AHJ.2010.03.004
P407
P577
2010-03-15T00:00:00Z